Healthcare stocks are mostly higher with the NYSE Healthcare
Sector Index gaining 0.3% and shares of healthcare companies in the
S&P 500 climbing 0.5% as a group.
In company news, Cytokinetics (
) is up nearly 2% to $11.13 a share, but off an early day high of
$11.62 after publishing Phase II trial data for its tirasemtiv drug
candidate in patients with Amyotrophic lateral sclerosis, or
The trials evaluated the tolerability of tirasemtiv at doses up
to 500 milligrams daily for up to three weeks, with the results
showing tirasemtiv was well-tolerated in these patients, with
dizziness the most common adverse event. As predicted from earlier
non-clinical and clinical studies, using tirasemtiv with riluzole
roughly doubled the plasma concentration of riluzole compared to
the administration of riluzole without tirasemtiv.
The test results were published in the journal Amyotrophic
Lateral Sclerosis and Frontotemporal Degeneration.
In other sector news,
(+) ONXX, (+1.7%) Reportedly agrees to give potential buyers,
including Amgen (
), access to trial data for its new cancer drug, removing a key
hurdle that's been holding up deal talks according to Reuters,
citing three people familiar with the matter.
(+) SNY, (+0.1%) Cut to Market Perform from Outperform at Cown
Copyright (C) 2014 MTNewswires.com. All rights reserved. Unauthorized reproduction is strictly prohibited.